Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Kiromic BioPharma is a clinical-stage biotherapeutics company developing allogeneic Gamma Delta T-cell therapies targeting solid tumors. Its proprietary AI platform identifies tumor-specific targets, enabling the creation of off-the-shelf immunotherapies. The company focuses on innovative, cost-effective cell products with potential for broad cancer treatment, leveraging bioinformatics, bioengineering, and GMP manufacturing to address unmet needs in oncology markets.
This description was generated via AI from an annual report. Updated about 1 year ago.